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Metastatic recurrence is the most important biological behavior of hepatocellular carcinoma (HCC) and
the main cause of treatment failure. Early prediction of metastasis is currently impossible due to the lack
of speciﬁc molecular probes to recognize metastatic HCC cells. Aptamers have recently emerged as
promising potential molecular probes for biomedical applications. Two well-matched HCC cell lines
including HCCLM9 with high metastatic potential and MHCC97-L with low metastatic potential, were
used to select aptamers for HCC metastasis. With a whole-cell-SELEX strategy, in which HCCLM9 cells
were used as target cells and MHCC97-L cells as subtractive cell, 6 potential aptamers had been
generated. Detailed study on selected aptamer LY-1 revealed that it could bind metastatic HCC cells with
high afﬁnity and speciﬁcity, not only in cells culture and animal models of HCC metastasis, but also in
clinical HCC specimens. Moreover, the aptamer LY-1 and magnetic particles conjugates could efﬁciently
capture the HCC cells from complex mixture whole blood. These studies demonstrated that this HCC
speciﬁc aptamer LY-1 could be a promising molecular probe to recognize metastatic HCC cells.
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Hepatocellular carcinoma (HCC) is one of the most common and
highly malignant tumors worldwide, accounting for about 6% of all
cancers [1,2]. The disease is particularly common in China, which
accounts for 53% of the global HCC cases. Although signiﬁcant
progress has been made in basic researches in HCC, the treatment
efﬁcacy remains poor, with 5-year survival rate around 5% [2,3]. For
patients with early HCC with tumor nodule< 5 cm in diameter, the
best treatment is resection with curative intent. Even for such pa-
tients, however, the 5-year recurrence rate is as high as 40e50% [3].
Post-operative recurrence and metastasis has long been the most
difﬁcult obstacle to durable treatment efﬁcacy and long-term
survival.
Currently, medical imaging exams and serum detection of
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C-ND license.recurrence and metastasis. But, AFP-positive HCC only accounts for
70e80% of HCC and ultrasound cannot detect tumor < 1 cm in
diameter [4]. Therefore, there is an urgent need for new tumor
markers for clinical application.
So far, both genomics and proteomics approaches have been
used to search for HCC metastasis-related markers [5,6], resulting
in deep insights into the mechanism of HCC recurrence and
metastasis.
It has been suggested that HCCmetastasis may occur at the early
stage of cancer development [3], and it involves multiple factors
and through many stages, including tumor cell proliferation,
adhesion, invasion, extracellular matrix degradation, angiogenesis
and cell motility. In general, HCC metastasis is inﬂuenced by the
constant interactions between HCC cells and the tumor microen-
vironment, resulting in particular tumor cell molecular phenotypes
and biological characteristics favoring metastatic progression [7,8].
Indeed recent studies have shown the signiﬁcance of tumor cell
surface molecules in HCC metastasis, such as E-cadherin, b-catenin,
laminin, CD44 and ICAM-1, which are important for tumor cell
adhesion, invasion and movement [9e11].
Human HCC cell lines MHCC97-L with low metastatic potential
and HCCLM9 with high metastatic potential are ideal cell models
for the comparative study of HCC metastasis [12]. Both cell lines
Fig. 1. Enrichment of HCC metastasis-related aptamers using subtractive cell-SELEX strategy. (A) After 9 rounds of enrichment, the single strand DNA bound to HCCLM9 was eluted
and ampliﬁed by PCR to produce double strand DNA for further analysis. (A1), a 76 bp double strand DNA lane was obtained after 8 cycles of PCR; (A2), the same product as A1 after
10 cycles of PCR; (A3), negative control of PCR; (A4), using the double strand DNA from A1 as template, double strand DNAwas obtained after 4 cycles of PCR; (A5eA7), the same as
A4 after 6, 8 and 10 cycles of PCR, respectively. (B) After 10 rounds of enrichment, the single strand DNA bound to HCCLM9 was eluted and ampliﬁed by PCR, but did not produce the
76 bp DNA lane, even after 10, 12, 14 and 16 cycles of PCR (B1-B4). (B5) negative control of PCR. Molecular marker (from top to bottom) was 700 bp to 25 bp.
F.-B. Wang et al. / Biomaterials 34 (2013) 3816e3827 3817were derived from the same patient, so they share the same genetic
background but have dramatically different metastasis potentials.
Therefore, these cell lines could help search for cell surface speciﬁc
molecules on HCCLM9, for both prediction and treatment of
metastasis and recurrence.
SELEX stands for systematic evolution of ligands by exponential
enrichment [13], which is an efﬁcient strategy for high throughput
in vitro selection of bio-library pool. The technology usually takes
repetitive in vitro selection and PCR ampliﬁcation, to obtain
aptamers which are short single-stranded nucleic acid oligomers
with a speciﬁc three-dimensional conﬁguration, enabling them
well-ﬁttingly and speciﬁcally bind to target molecules. Aptamers
have a wide application in clinical diagnosis, basic researches and
drug developments because of their unique features including
speciﬁc recognition, no immunogenicity, easy chemosynthesis and
modiﬁcation [14]. In recent years, a modiﬁed SELEX process using
whole living cells as target was developed and designated as
cell-SELEX [15], which could select aptamers from unknown com-
plex targets.
Presently there have been no researches on applying subtractive
cell-SELEX method to select DNA-aptamers speciﬁcally binding to
human metastatic HCC cells surface molecules. This study wasFig. 2. Flow cytometry assay to monitor the binding of selected library with HCCLM9 (ta
signiﬁcant increases in ﬂuorescence intensity were detected on HCCLM9 cells (panel A) but n
Increasing ﬂuorescence intensity bound to HCCLM9 with the 3, 5, 7 and 9 rounds of selecte
selected library by ﬂow cytomtry.designed to identify single-strand DNA-aptamers (cell-molecular
probe) that speciﬁcally recognize surface molecules of HCCLM9
but not MHCC97-L. Subtractive cell-SELEX strategy was used to
generate aptamers, using MHCC97-L as subtractive cells and
HCCLM9 as target cells. Flow cytometry assay was applied to
determine enrichment of aptamers library pool, the binding afﬁnity
and speciﬁcity of the selected aptamers. Then the candidate
DNA-aptamers were conjugated with biotin to form speciﬁc bio-
probes to recognize HCC cells in cultured cell lines, animal models
of HCC and human HCC tissues. Furthermore, the biotin-conjugated
aptamer was coupled with magnetic particles to capture HCC cells
in experimental conditions mimic human peripheral blood.
2. Materials and methods
2.1. Cell lines
MHCC97-L cell (low metastatic potential, used as subtractive control cell in this
study) and HCCLM9 cell (high metastatic potential, used as target cell in this study)
were established from the same parent cell line MHCC97 [12]. Other HCC cell lines
HepG2 and Huh-7, human breast cancer cell line MDA-MB-231, human lung cancer
cell line H1299, Human colon adenocarcinoma cell line SW48, human gastric cancer
cell line MGC803, and human cervical cancer cell line HeLa were maintained at our
laboratory.rget cells) and MHCC97-L (subtractive cells). With increasing rounds of enrichment,
ot on MHCC97-L (panel B), suggesting the enrichment of HCCLM9 speciﬁc aptamers. (A)
d library; (B) Fluorescence intensity bound on MHCC97-L with the 3, 5, 7 and 9 rounds
Fig. 3. Multiple sequence alignment analysis, sequencing and structure prediction of aptamer LY-1. (A)The sequence analysis of LY-1 aptamer generated from HCCLM9 cells, with a
38 bp core sequence marked in red font. (B) The homologous analysis of aptamers generated from HCCLM9 cells. (C) The structure prediction of aptamer LY-1 generated from
HCCLM9 cells. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 4. The ﬂuorescence intensity of the selected aptamers bound to HCCLM9 cells by
ﬂow cytometry analysis. Compared with control, all the selected aptamers had in-
creases ﬂuorescence intensity, and the LY-1 the highest.
F.-B. Wang et al. / Biomaterials 34 (2013) 3816e382738182.2. Antibodies and reagents
Rabbit anti-human monoclonal antibody cytokeratin (CK) 19 and mouse anti-
human AFP monoclonal antibody were purchased from R&D Systems. PE-CD45
(mouse anti-human) monoclonal antibody was purchased from BD Biosciences.
Yeast tRNA and BSA and Salmon sperm DNA were purchased from Fisher Scientiﬁc
(Thermo Fisher Scientiﬁc Inc., USA). Streptavidin coated magnetic particles (Dyna-
beads, M-280 Streptavidin) used for separating the single strand DNA and capturing
cells and QD605-streptiavidine were purchased from Invitrogen. The AmpliTaq Gold
360 PCRMasterMixwaspurchased fromABI (Applied Biosystems Inc., Foster City, CA).
The FITC-labeled control aptamer NK8 (bound to Mycobacterium tuberculosis) [37]
was synthesized by SBS Genetech Co., Ltd (Shanghai, China) and puriﬁed by reverse
phase high performance liquid chromatography (HPLC) (Agilent Technologies, USA).
2.3. Random DNA library and primers
The cell-SELEX DNA library contains a 40-base central random sequence ﬂanked
by primer sites on either side (50-ATC CAG AGT GAC GCA GCA-N40-TGG ACA CGG
TGG CTT AGT-30). The FITC-labeled forward primer (50-FITC-ATC CAG AGT GAC GCA
GCA-30) and biotin-labeled reverse primer (50- Bio-ACT AAG CCA CCG TGT CCA-30)
were used in PCR to obtain the double-labeled DNA and to separate the single-
stranded DNA by streptavidin-coated magnetic particles. The FITC-labeled se-
quences were used to monitor progress of selection by ﬂow cytometry (Beckman
Coulter, USA). All sequences were synthesized by SBS Genetech Co., Ltd and puriﬁed
by reverse phase HPLC.
2.4. Cell culture
HCC cell lines MHCC97-L, HCCLM9, HepG2 and Huh-7, human breast cancer cell
line MDA-MB-231, human lung cancer cell line H1299, human colon adenocarci-
noma cell line SW48, human gastric cancer cell line MGC803, and human cervicalcancer cell line HeLa were cultured in high glucose DMEM with 10% FBS and incu-
bated at 37 C in a humidiﬁed atmosphere containing 5% CO2.
2.5. Subtractive cell-SELEX procedure [15]
In this study, HCCLM9 was used as target cells and MHCC97-L as subtractive
cells. Both cell lines were counted and tested for viability before experiments. The
F.-B. Wang et al. / Biomaterials 34 (2013) 3816e3827 3819ssDNA library (8 nmol) was ﬁrst denatured at 95 C for 5 min and kept on ice for
10 min, then dissolved in 1 mL pre-cooled binding buffer (PBS- 1 M MgCl2 -0.1 mg/
mL yeast tRNA-1 mg/mL BSA-0.1 mg/mL Salmon sperm DNA). Target cells (1  107)
were washed, dissociated (PBS -0.02% EDTA), and then incubated with the ssDNA
library on ice in an orbital shaker for 60 min. After incubation, the cells were washed
3 times to remove unbound DNA sequences. DNase-free water (500 ml) was added to
the adhesive cells, which were scraped off, re-suspended and transferred into a
1.5 mL microfuge tube. The cell mixture was heated at 100 C for 5 min, centrifuged
at 13,100 g for 5 min and the supernatant containing eluted ssDNA was collected.
The bound sequences were ampliﬁed by PCR using FITC- and biotin-labeled primers,
using ABI 9600 Cycler (Applied Biosystems Inc., Foster City, CA, USA) at 95 C for 40 s,
56 C for 40 s, and 72 C for 40 s, followed by the ﬁnal extension for 7 min at 72 C.
The selected sense ssDNA strands were separated from the biotinylated antisense
ssDNA by streptavidin-coated magnetic particles (Dynabeads, M-280 Streptavidin,
Invitrogen) and alkaline denaturation. From the fourth round of selection, the
selected DNA pool was used to perform subtractive selection (the selected DNA poolFig. 5. The ﬂuorescence imaging of selected aptamers bound to HCCLM9 cells by ﬂuorescent
The ﬂuorescence imaging of aptamer LY-13 bound to HCCLM9 cells. (B) The ﬂuorescence ima
LY-32 bound to HCCLM9 cells. (D) The ﬂuorescence imaging of aptamer LY-27/45 bound to H
The ﬂuorescence imaging of aptamer LY-7/43 bound to HCCLM9 cells.ﬁrstly incubated with subtractive cells, then the supernatant containing unbound
ssDNA sequence incubated with target cells) to ﬁlter out sequences that may bind to
the molecules on both the target and subtractive cell lines. To enrich the aptamers
with high afﬁnity and speciﬁcity, the washing stringency was enhanced gradually by
extending the washing time with increasing volume of washing buffer and
increasing the number of washes. Furthermore, the target cell number and the
concentration of ssDNA pool and the incubation time were gradually reduced. The
entire selection process was repeated according to the extent of enrichment, as
monitored by ﬂow cytometry. The detailed procedures were listed in Table 1 (see
supplementary data).
2.6. Flow cytometry to monitor the binding of enriched ssDNA pool
To monitor the binding of enriched ssDNA pool during cell-SELEX, FITC-labeled
ssDNA pools were incubated with target cells HCCLM9 or subtractive cells MHCC97-
L (1  106 for each) in 500 mL binding buffer on ice for 30 min. Cells were washedmicrocopy analysis. All the aptamers had obvious cell membrane binding property. (A)
ging of aptamer LY-1 bound to HCCLM9 cells. (C) The ﬂuorescence imaging of aptamer
CCLM9 cells. (E) The ﬂuorescence imaging of aptamer LY-46 bound to HCCLM9 cells. (F)
F.-B. Wang et al. / Biomaterials 34 (2013) 3816e38273820twice after incubation and the ﬂuorescence intensity was determined by ﬂow
cytometry. The FITC-labeled control aptamer NK8 (bound to Mycobacterium
tuberculosis) [37] was used as a negative control. The 3, 5, 7, and 9 rounds of
enriched ssDNA pool were analyzed by ﬂow cytometry (Beckman Coulter, USA).
2.7. Cloning and sequencing of enriched ssDNA pool and multiple sequence
alignment analysis
In this study, 10 rounds of selection were performed. On the basis the
ﬂow cytometry results, the enriched ssDNA pool of 9 rounds of selection was
PCR-ampliﬁed using unmodiﬁed primers and cloned into Escherichia coli using the
TA cloning kit (Invitrogen). The candidate aptamer sequences were determined by
Invitrogen Co., Ltd (Shanghai, China). The sequencing results were subjected to
multiple sequence alignment analysis with the DNAMAN (version7 Lynnon Corpo-
ration, Quebec, Canada) to identify highly conserved motifs in the selected DNA
sequences. The conserved sequences with high repeats among selected pools were
then synthesized and tested for speciﬁcity and afﬁnity.
2.8. Flow cytometry to study the binding afﬁnity and speciﬁcity
The selected aptamers were synthesized and labeled with FITC. The screening of
potential aptamers and the binding afﬁnity assay were performed using ﬂow
cytometry. The aptamers with the best binding afﬁnity (high ﬂuorescence intensity)
were chosen to further identify the binding afﬁnity constant and speciﬁcity. To
determine the binding afﬁnity of the aptamers, target cells (1 106) were incubated
with varying concentrations of FITC-labeled aptamer in 500 mL binding buffer on iceFig. 6. The binding speciﬁcity study of aptamer LY-1 to different cancer cell lines as determ
HCCLM9, but no changes in other cancer cell lines, indicating that aptamer LY-1 was speciﬁfor 30 min. Cells were washed twice after incubation and the ﬂuorescence intensity
was determined by ﬂow cytometry. The FITC-labeled control aptamer NK8 was used
as negative control. All binding assays were in triplicate. The mean ﬂuorescence
intensity of the control aptamer NK8 was subtracted from that of the aptamer with
the target cells to determine the speciﬁc binding of the labeled aptamer. The equi-
librium dissociation constant (Kd) of the aptamerecell interaction was obtained by
ﬁtting the dependence of intensity of speciﬁc binding on the concentration of the
aptamers to the equation Y ¼ B max X/(kd þ X), using Prism software (V5.0 trial,
GraphPad Software, Inc, CA, USA). To determine the cell speciﬁcity of the selected
aptamer, human cancer cell lines including HCC cell lines MHCC97-L, HepG2 and
Huh-7, breast cancer cell line MDA-MB-231, lung cancer cell line H1299, colon
adenocarcinoma cell line SW48, gastric cancer cell line MGC803, cervical cancer cell
line HeLa, and peripheral blood white cells (WBC) were used in binding assays by
ﬂow cytometry.
2.9. Veriﬁcation of the selected aptamer possible binding sites on target cell by ﬂow
cytometry
To verify the binding of aptamers to target cell-surface markers, cells were
examined by enzymatic treatment. The cultured target cells werewashed twicewith
PBS, then incubated with 1 mL Trypsin-free cell dissociation solution (PBS-0.02%
EDTA) or 1 mL Trypsin-free cell dissociation solution (PBS-0.02% EDTA) containing
0.1 mg/mL proteinase K in PBS at room temperature for 10 min. To quench the
proteinase digestion, the target cells were quickly mixed with 1 mL pre-cooled PBS
(containing 10% FBS). Then the treated cells (1  106) were used for the aptamer
binding assay by ﬂow cytometry described as above.ined by ﬂow cytometry. There was a signiﬁcant increase in ﬂuorescence intensity in
c to HCCLM9.
Fig. 8. Binding curve of the aptamer LY-1 with target cells HCCLM9. Cells were incu-
bated with varying concentrations of FITC-labeled aptamer in triplicate. The mean
ﬂuorescence intensity of the control aptamer (background binding) at each concen-
tration was subtracted from the mean ﬂuorescence intensity of the corresponding
aptamer.
Fig. 7. The ﬂuorescence imaging and ﬂuorescence intensity of selected aptamer LY-1 bound to WBC by ﬂuorescent microcopy and ﬂow cytometry analysis. Both results indicated
that LY-1 aptamer was not speciﬁc to WBC. (A) The ﬂuorescence imaging of control aptamer unbound to WBC. (B) The ﬂuorescence imaging of aptamer LY-1 unbound to WBC.
F.-B. Wang et al. / Biomaterials 34 (2013) 3816e3827 38212.10. Fluorescence imaging of live cells bound to the selected aptamer
The FITC or biotin 50-tagged aptamer was synthesized by SBS Genetech Co., Ltd
(Shanghai, China). Cells were cultured in chamber slides, grown overnight, and
rinsed with PBS. For ﬂuorescence imaging, the selected individual aptamer labeled
with FITC or biotin was incubated with cell monolayer in chamber slides in binding
buffer on ice for 30 min. After washing, the cells incubated with the biotinylated
aptamer were then continued to incubate with QD605-streptiavidine (Q10101MP,
invitrogen) at room temperature for 30 min. Cells bound to FITC- or QD605-labled
aptamer were imaged with Olympus BX51 ﬂuorescence microscope equipped
with an Olympus DP72 camera (Olympus Optical Co., Ltd., Tokyo, Japan).
2.11. Nude mice model of HCC spontaneous pulmonary metastasis
Male athymic BALB/c nu/numice, 4-wk old, were obtained from Beijing HFK Bio-
Technology Co., Ltd [animal quality certiﬁcate No. SCXK(Jing) 2009-0004] and
maintained in an Animal Biosafety Level 3 Laboratory at the Animal Experimental
Center of Wuhan University. After 3 days of adaptation, the animals were used for
in vivo study, and the protocols were approved by the Animal Care Committee of
Wuhan University. HCCLM9- nudemice were produced as described previously [12].
All mice were sacriﬁced under deep anesthesia by peritoneal injection of 3%
pentobarbital sodium in approximately 6 wks after model construction. Liver and
lung samples were collected and stored at 80 C refrigerator. Some lung samples
were ﬁxed in 10% neutral formalin solution and embedded in parafﬁn. Four
micrometer thick sections were cut from each parafﬁn block and stained with he-
matoxylin and eosin for microscopic examination to validate lung metastasis.
2.12. Recognition of the HCC cells in mice model tumor tissue and clinical specimens
by the selected aptamer LY-1 labeled with QD605
Preparation for the formalin-ﬁxed parafﬁn-embedded mice model liver tumor,
lung metastasis tumor tissues, and clinical specimens were briefed as the following.
Tissue sections (4 mm thick) were preheated at 60 C for 2 h and then deparafﬁnized
in xylene 3 times each for 5 min. Tissue hydration was carried out by a series of
immersion steps at decreasing ethanol concentrations (100%, 95%, 95% and 85%
ethanol for 5, 2, 2, and 2 min, respectively), followed by rinsing in water for 5 min.
The slides were pretreated in 0.01 M citrate buffer (pH 6.0) and heated in a mi-
crowave oven at 98 C for 20 min for antigen retrieval. After cooling down in the
citrate buffer for another 30min at room temperature, the tissue slides werewashed
in water before use. For ﬂuorescence aptamer staining, tissue sections were blocked
with pre-cooled binding buffer (PBS- 1 M MgCl2 -0.1 mg/mL yeast tRNA-1 mg/
mLBSA-0.1 mg/mL Salmon sperm DNA) at 4 C for 60 min and then incubated with
biotinlated aptamer in binding buffer. After incubation at 4 C for 60 min, these
tissue sections were washed 3 times with PBS. After washing, these tissue sections
were then continued to incubate with QD605-streptiavidine at room temperature
for 30 min. Finally, the stained sections were imaged by an Olympus BX51 ﬂuores-
cence microscope equipped with an Olympus DP72 camera (Olympus Optical Co.,
Ltd., Tokyo, Japan).
2.13. Blood and tumor tissue clinical samples collection
To prepare for artiﬁcial blood samples environment, peripheral blood samples
were collected in EDTA-K2 anticoagulant tube from healthy male volunteers. HCC
specimens from 66 patients were obtained from the Department of Pathology at
Wuhan University Zhongnan Hospital and Hubei Cancer Hospital. All tumors were
ﬁxed with formalin and embedded with parafﬁn. Pathological diagnosis was made
according to the histology of tumor specimens and examined by experienced pa-
thologists. Major clinic-pathological characteristics of these patients were listed in
Table 2 (see supplementary data).2.14. Recognition of the HCC cells in real peripheral blood samples using the selected
aptamer LY-1 labeled with FITC
To evaluate the recognition capacity of the selected aptamer in a complex bio-
logical environment, HCCLM9 cells (1 105) were prepared as described above and
mixed with the whole blood. After lysis of red blood cells in NH4Cl solution, the
remaining cells (HCCLM9 cells andWBC) were incubated with FITC-labeled aptamer
and PE-CD45 (BD Biosciences) on ice for 30 min. After incubation and washing, the
samples were analyzed by ﬂow cytometry. In order to test the recognition sensitivity
of the FITC-labeled aptamer, different amounts HCCLM9 cells (104, 103 and 102 HCC
cells) were respectively mixed with thewhole blood, the other treatment steps were
the same as described above.
2.15. Capture the HCC cells in real peripheral blood samples by the aptamer-
conjugated magnetic particles
To evaluate the targeting capture capacity of the selected aptamer LY-1 in a
complex biological environment, HCCLM9 cells (1105) were prepared as described
above andmixedwith thewhole blood. After lysis of red blood cells in NH4Cl solution,
the remaining cells (HCCLM9 cells and WBC) were incubated with bio-labeled
aptamer on ice for 30 min. After washing, the cells were then incubated with
streptavidin-coated magnetic particles (Dynabeads, M-280 Streptavidin) at room
temperature for 30min. Afterwashing, the suspension of the cells-aptamer-magnetic
particles was dropped on the glass slides pre-treated with poly-lysine. After being
dried in roomair, the slideswere gentlywashed once in PBS and immediatelyﬁxed for
5 min in methanol solution which was pre-cooled at 20 C. The cells were ﬁrst
incubated with rabbit anti-human keratin 19 and mouse anti-human AFP primary
anti-bodies (R&D Systems) overnight at 4 C, then washed and incubated with
FITC-conjugated anti-rabbit or anti-mouse IgG secondary antibody (dilution 1:200,
Santa Cruz Biotechnology Inc) for 60 min at room temperature. In order to evaluate
the capture efﬁciency of the aptamer-conjugated magnetic particles, different
amounts HCCLM9 cells (104, 103 and 102 HCC cells) were respectively mixed with the
whole blood. The other treatment steps were the same as described above.
Fig. 9. Possible binding sites of aptamer LY-1 to target cell as determined by cytometry and ﬂuorescence microcopy. Without proteinase K treatment, the HCCLM9 cells had
signiﬁcant cell membrane binding to LY-1 (panel A and red curve of panel B). After proteinase K treatment, there was remarkable decrease in cell membrane ﬂuorescence intensity
(the blue curve of panel B). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
F.-B. Wang et al. / Biomaterials 34 (2013) 3816e382738223. Results
3.1. Selection and identiﬁcation of HCC metastasis-related aptamers
Using subtracted cell-SELEX strategy with MHCC97-L as sub-
tractive cells and HCCLM9 as target cells, we screened one DNA lane
after 9 rounds of enrichment (Fig. 1A). On further enrichment, this
DNA lane disappeared (Fig. 1B). Therefore it was concluded that 9
rounds of enrichment was optimal. We further evaluated the
selected DNA strands using ﬂow cytometry (Fig. 2). With increasing
number of enrichment up to 9 rounds of selection, the ﬂuorescence
intensity bound on HCCLM9 cells increased signiﬁcantly (Fig. 2A),
while there was no change in ﬂuorescence intensity on MHCC97-L
cells (Fig. 2B). Therefore, it was evident that the selected single
strand DNA had preferential and speciﬁc binding to HCCLM9 cells.3.2. Selection, sequencing and structure prediction of HCCLM9
speciﬁc aptamers
After 9 rounds of the enrichment, the selected ssDNA library was
PCR-ampliﬁed and cloned into Escherichia coli. Fifty clones were
subjected to sequence study and deﬁnite results were obtained
from 38 clones, including 23 clones yielding the same sequenceFig. 10. The QD605 ﬂuorescence imaging of the selected aptamer Lnamed as LY-1, 9 clones yielding the same sequence named as
LY-13, 2 clones yielding the same sequence named as LY-7/43,
another 2 clones yielding the same sequence named as LY-27/45,
and the remaining 2 clones each yielding one sequence named as
LY-32 and LY-46. After sequence analysis (Fig. 3A), homologous
analysis (Fig. 3B) and structure prediction (Fig. 3C), these 6
aptamers were labeled with FITC at the 50end, and their binding
afﬁnity to HCCLM9 cells was evaluated. Both ﬂow cytometry and
ﬂuorescent microcopy assays (Fig. 4 and Fig. 5) revealed that LY-1
had the highest binding capacity. Therefore, LY-1 was selected for
detailed study.3.3. Binding study of LY-1
Different HCC cells (HCCLM9, MHCC97-L, Huh-7 and HepG2),
human lung cancer cell line H1299, human colon adenocarcinoma
cell line SW48, human gastric cancer cell line MGC803, human
cervical cancer cell line HeLa, human breast cancer cell line
MDA-MB-231, and human peripheral WBC were used to test the
binding speciﬁcity of LY-1. As shown in Fig. 6 and Fig. 7, LY-1 had
highly speciﬁc binding capacity to HCCLM9 and low speciﬁc bind-
ing capacity to MHCC97-L, but no or little binding to other cancer
cells andWBC. The apparent dissociation constants (Kd) of the LY-1Y-1 bound to HCCLM9 cells by ﬂuorescent microcopy analysis.
F.-B. Wang et al. / Biomaterials 34 (2013) 3816e3827 3823aptamerecell interaction was Kd ¼ 167.3  30.2 nM (Fig. 8). In
order to investigate the possible binding site of LY-1, ﬂuorescence
binding assays were conducted before and after HCCLM9 cells were
treated with proteinase K. As shown in Fig. 9, there was evident cell
membrane ﬂuorescence before proteinase K treatment (Fig. 9A and
Fig. 9B red line), and signiﬁcantly ﬂuorescence decrease after pro-
teinase K treatment (Fig. 9B blue line). These results suggest that
the binding site of the aptamer LY-1 is most likely on the cell
membrane of HCCLM9.Fig. 11. The QD605 ﬂuorescence imaging of the aptamer LY-1 bound to HCCLM9 cells in the
and HCC cells in the formalin-ﬁxed parafﬁn-embedded human HCC tissues from patients. (A
aptamer unbound to the HCC cells in mice model liver tumor tissue; (C) aptamer LY-1 bound
unbound to the HCC cells in mice model lung metastasis tumor tissue; (E) aptamer LY-1 bou
cells in human HCC tissue.3.4. QD605 labeled LY-1 aptamer as speciﬁc molecular probe to
recognize HCC cells in cell culture, animal models tissue and clinical
HCC specimens
We then explored the possibility whether the LY-1 aptamer
could be a potential probe to recognize HCC cells in vitro.
Biotinlated-LY-1 aptamer was ﬁrst added to cultured cells, followed
by QD605-streptiavidine. As shown in Fig. 10, there was high
QD605 ﬂuorescence on the cell membrane in cultured HCCLM9formalin-ﬁxed parafﬁn-embedded mice liver tumor and lung metastasis tumor tissues
) aptamer LY-1 bound to the HCC cells in mice model liver tumor tissue; (B) The control
to the HCC cells in mice model lung metastasis tumor tissue; (D) The control aptamer
nd to the HCC cells in human HCC tissue; (F) The control aptamer unbound to the HCC
F.-B. Wang et al. / Biomaterials 34 (2013) 3816e38273824cells. Furthermore, in the xenograft model of HCCLM9, the HCC cells
in both the liver tumor (Fig.11A and B) and lungmetastasis (Fig. 11C
and D) were also clearly stained by this probe.
Moreover, among the 66 HCC specimens, there were 6 speci-
mens with clear and speciﬁc QD605-LY-1 labeling (Fig. 11E and F).
The 6 HCC patients were all positive for serum hepatitis B surface
antigen (HBsAg), elevated serum AFP and distant metastasis.
Detailed information on these 6 patients was listed in Table 3 (see
supplementary data).
3.5. FITC labeled LY-1 to recognize HCC cells in peripheral blood
To test whether aptamer LY-1 could identify HCC cells in a
simulated peripheral blood environment, we mixed 105, 104, 103
and 102 HCCLM9 cells into 1 mL of peripheral blood from a healthy
volunteer, respectively. After lysis of erythrocytes with NH4Cl so-
lution, the suspension containing HCCLM9 cells was incubatedwith
FITC-labeled LY-1 aptamer on ice. Flow cytometric study (Fig. 12)
demonstrated that as few as 102 HCC cells in 1 mL of peripheral
blood could be identiﬁed by the FITC-labeled LY-1 aptamer.
3.6. Capture of circulating HCC cells based on aptamer LY-1
conjugated magnetic particles
We used aptamer LY-1 as recognition molecule and magnetic
particles as separation media to capture circulating HCC cells. We
mixed 105, 104, 103 and 102 HCC cells into 1 mL of peripheral blood
from a healthy volunteer, respectively. After lysis of erythrocytes
with NH4Cl solution, the suspension containing HCCLM9 cells was
incubated with biotinlated-labeled aptamer LY-1 on ice, and then
circulating HCC cells were captured by streptavidin-coatedFig. 12. Recognition of the HCCLM9 cells by the molecular probe aptamer LY-1 in the comp
monoclonal antibody PE-CD45 were used to detect the HCC cells mixed with WBC. The ap
other blood cells. The FITC-labeled aptamer LY-1 could recognize HCC cells when (A) 105, (magnetic particles. The captured cells were further identiﬁed by
immunoﬂuorescence cytochemistry to recognize AFP and CK19,
and DAPI to stain the nuclei. As shown in Fig.13, the circulating HCC
cells were indeed surrounded by magnetic particles, suggesting
speciﬁc capture of these cells. It was also found that 2 HCC cells
could be captured from 1 mL peripheral blood containing 102 HCC
cells by the magnetic particles-aptamer conjugates.4. Discussion
Themost important biological behaviors of malignant tumor are
invasion andmetastasis, which seriously affect the tumor prognosis
[16]. These behaviors are closely associated with the cancer cell
invasiveness, and tumor cell membrane molecules are directly
involved in many aggressive behaviors such as adhesion, invasion
and movement [9e11,16]. The composition and characteristics of
cell membrane proteins are modiﬁed during malignant trans-
formation and make them likely candidates for cancer biomarkers
[9,17]. The identiﬁcation of tumor cell membrane protein targets is
important in understanding tumor progression, developing diag-
nostic tools, and identifying new therapeutic targets [17,18]. Correct
understanding of tumor cell surface protein requires efﬁcient mo-
lecular probes to recognize them. To be effectively used for tumor
diagnosis, classiﬁcation and therapy, such probes should have
speciﬁc binding to target tumor cells [19,20]. Aptamers, as DNA/
RNA probes, could help address such challenges by recognizing
proteins, peptides and other small molecules with high afﬁnity and
speciﬁcity [19,21].
Recently, aptamer selection against complex targets, especially
whole live cells, has attracted increasing attention. Using the
cell-SELEX approach, several promising aptamers have beenlex mixture with whole blood from healthy volunteer. FITC-labeled aptamer LY-1 and
tamer LY-1 only recognized the HCC cells and did not bind to CD45-positive WBC and
B) 104, (C) 103 and (D) 102 HCCLM9 cells mixed into the 1 mL peripheral whole blood.
Fig. 13. Capture of the HCCLM9 cells by biotinated apatamer LY-1 as recognition molecular probe and streptavidin-coated magnetic particles as separation medium in the complex
mixture with whole blood from healthy volunteer. The captured cells were stained with monoclonal anti-bodies against AFP and CK19. The nucleus of the captured cells was also
stained by the nucleic acid organic dye DAPI. When 1  104 HCCLM9 cells mixed into the 1 mL of peripheral whole blood, the aptamer LY-1 -magnetic particles conjugates could
speciﬁcally recognize and capture HCC cells.
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lung cancer [22], liver cancer (mouse) [23], and lymphocytic and
myeloid leukemia [19]. To our knowledge, there has been no report
on using aptamer strategy to select metastasis-related cell surface
molecules from highly metastatic human HCC cell lines. In our
study, we modiﬁed the subtractive cell-SELEX strategy, using the
highly metastatic HCCLM9 as target cells and the low metastatic
MHCC97-L as subtractive cells, through 9 rounds of selection and
identiﬁcation by both ﬂow cytometry and ﬂuorescence imaging,
obtained a speciﬁc aptamer LY-1, binding the highly metastatic
human HCC cell membrane surface with high afﬁnity. To test
whether aptamer LY-1 could be used for HCC cells speciﬁc recog-
nition, other cancer cells from lung cancer, breast cancer, colorectal
cancer, gastric cancer and cervical cancer and WBC were used as
control, the aptamer LY-1 showed speciﬁc targeting to HCCLM9
cells and little or no response to other cancer cells. To our knowl-
edge, this is the ﬁrst report on aptamers against highly metastatic
human HCC cells. The speciﬁc molecular probe aptamer LY-1
generated from cell-SELEX provide basis for clinical application.
The speciﬁc recognition of targets in complex clinical samples
remains a major challenge for many molecular probes. To deter-
mine the capability of aptamer LY-1 as a molecular probe for spe-
ciﬁc receptor recognition, we used aptamer LY-1 to identify HCC
cells in complex clinical samples (tissue and whole blood). Quan-
tum dots (QDs) have been developed as labels for the sensitive
detection [20]. Compared with organic ﬂuorescent dyes, QDs are
relatively photostable and have a very broad excitation range,making them better for imaging detection [24,25]. In this study,
QDs-labeled aptamer LY-1 was used to recognize HCC cells cultured
in vitro, HCC cells in the liver and lung tissue sections from the
animal model of HCC with lung metastasis, and HCC cells from
clinical liver cancer tissues. These studies demonstrated that the
functionalized aptamer LY-1 labeled with QDs could recognize not
only the highly metastatic HCC cells cultured in vitro, but also HCC
cells in liver and lung tissue section in animal model of lung
metastasis, and more importantly HCC cells in clinical liver cancer
tissues. Based on the speciﬁc binding of aptamer LY-1 to highly
metastatic HCC cells, we hypothesized that the HCC cells identiﬁed
by aptamer LY-1 in clinical liver cancer tissues have high metastatic
potential, if this hypothesis proved to be correct by additional tests
and related clinical information, the molecular probe aptamer LY-1
conjugated QDs would be used in target molecular imaging of HCC
and predict early metastasis of HCC. The capacity of the selected
aptamer LY-1 to identify the highly metastatic HCC cells in complex
tissue specimensmakes it a potentially effective molecular probe to
recognize HCC for both diagnostic and therapeutic applications.
To conﬁrmwhether the aptamer LY-1 could identify HCC cells in
a simulated peripheral blood environment, FITC-labeled aptamer
LY-1 and monoclonal antibody CD45 were used to detect HCC cells
mixed with normal human whole blood. The aptamer LY-1 only
recognized the HCC cells and did not bind to CD45-positive WBC
and other blood cells. We also found that HCC cells could be
identiﬁed from 1 mL peripheral blood containing 102 HCC cells by
the FITC-labeled aptamer LY-1. These studies indicate that this
F.-B. Wang et al. / Biomaterials 34 (2013) 3816e38273826aptamer could serve as a targeting molecule to capture circulating
HCC cells.
Circulating tumor cells (CTCs) have a feature of "self-seeding"
[26], which means they can return to the primary tumor to develop
and enhance tumor growth. CTCs are important in prognostic
evaluation, early detection of metastasis and individualized treat-
ment. Due to lack of speciﬁc target molecules, the clinical detection
of circulating HCC cells is not possible. So far, technologies of CTCs
enrichment and separation are mostly based on density gradient
centrifugation, cell size-based membrane ﬁltration and immuno-
magnetic particles capture [27]. The standard method of CTCs
separation is magnetic activated cell sorting technology based on
the tumor cell surface epithelial antigen. Epithelial cell adhesion
molecule (EpCAM) is a speciﬁc adhesion molecule widely
expressed on surfaces of epithelial cells and tumor cells of epithelial
origin. Cellsearch system based on EpCAM antibody beads has been
applied to detect CTCs of breast cancer [28], colon cancer [29] and
prostate cancer [30]. Though HCC cells are epithelial cells, EpCAM is
only expressed in about 35% of HCC tissue samples [31]. Moreover,
epithelial CTCs may lose epithelial markers during dissemination
through the process called epithelial-to-mesenchymal transition
(EMT). Cellsearch system is not suitable for the separation, detec-
tion of circulating hepatocellular carcinoma cells [32]. Tan et al. [33]
developed a method to rapidly collect and detect leukemia cells
from whole blood samples using a two-nanoparticle assay with
aptamers as the molecular recognition probe, in which the
aptamer-integrated magnetic nanoparticles were used for target
cell extraction, and aptamer-integrated ﬂuorescent nanoparticles
were used for sensitive cell detection. In our study, the molecular
probe aptamer LY-1 conjugated magnetic particles was used for
target cell recognition and extraction, the human antibody AFP and
CK19 and the nucleic acid organic dye DAPI were used for cell
identiﬁcation. Our ﬁndings suggest that aptamer LY-1 conjugated
magnetic particles could be speciﬁc molecular probe to recognize
and capture circulating HCC cells from peripheral blood, using
strategies such as the nucleic acid aptamer-based microﬂuidic chip.
Indeed, there are some groups that have developed a highly sen-
sitive method for rapid capture of target cells based on aptamers
combined with microﬂudic chip [21,34e36].
5. Conclusion
In summary, using whole living cell-SELEX system, we screened
out a molecular probe aptamer LY-1 that can distinguish the high
metastatic potential human HCC cell from other cells, and validated
its speciﬁcity and sensitivity as potential molecular probes. When
combined with ﬂuorescent nanoparticles QDs, the aptamer LY-1-
QDs conjugates could speciﬁcally recognize not only highly meta-
static HCC cells in liver and lung tissue section in animal model but
also in clinical specimens. Furthermore, the aptamer LY-1- mag-
netic particles conjugates could effectively detect and extract
metastatic HCC cells from complex mixture whole blood. These
results suggest that aptamer LY-1 could be developed into a
promising molecular probe for early prediction HCC metastasis.
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